Invariant Natural Killer T Cell based Artificial T Cell Stimulator Development Service

Artificial T Cell Stimulators Enhance iNKT Cell-based Immunotherapies

NKT cells, a unique subset of immune cells with both T cell and natural killer cell characteristics, hold promise for immunotherapy. Invariant NKT (iNKT) cells, which can be stimulated by compounds such as α-galactosylceramide (α-GalCer), play a crucial role in immune responses and hold great promise for immunotherapy. Current immunotherapy often relies on the patient's own antigen-presenting cells, which can vary in quality and quantity. Artificial T cell stimulators offer a potential solution by mimicking these cells, providing a consistent and reliable way to activate NKT cells for therapeutic purposes, and overcoming the limitations of using patient-derived cells.

Fig.1 The crosstalk between iNKT cell and DC cell.^1,3

Invariant Natural Killer T Cell based Artificial T Cell Stimulator Development Service at Creative Biolabs

Creative Biolabs delivers a customized iNKT cell-based artificial T cell stimulator development service for global customers in iNKT cell-based immunotherapy improvement. Our service involves the whole process from artificial T cell stimulator design to function validation. By loading iNKT cell-specific activation signals into specific cells, it is expected to simulate natural antigen-presenting cells to achieve homogeneous iNKT cell activation. Leveraging our deep accumulation in immunology and cell biology, we can provide customers with high-quality and efficient services. In addition, we can customize the design of different types of stimulators according to the specific needs of our customers and flexibly adjust the intensity and duration of stimulation. At the same time, we have an efficient experimental platform and a professional technical team that can quickly deliver experimental results, helping customers accelerate scientific research progress and product development.

Key Components for iNKT Cell Activation

• Cd1 molecules-mediated antigen presentation
• Co-stimulatory molecules mediated iNKT cell activation
• Simulation of cytokine release by natural APC.

Benefits for You

• Enhanced iNKT Cell Activation: Homogeneous and robust iNKT cell activation surpassing the limitations of autologous APCs.
• Tailored Solutions: Customized design and development to meet your specific research needs and therapeutic goals.
• Accelerated Research: Rapid results delivery and streamlined workflows to expedite your research progress.
• Outstanding Expertise: Assistance with our profound experience in immunology, cell biology, and bioengineering.
• Improved Immunotherapy: Advance the development of novel iNKT cell-based immunotherapies for a range of diseases, including cancer and infectious diseases.

Associated Services

In addition to iNKT cell, Creative Biolabs offers a full range of specialized artificial T cell stimulator development services, including customized solutions for CD4+, CD8+, CD3+, CAR-T, and NK cells, enabling us the ability to contribute to a wide range of immunological research applications. Our dedication to exceeding customer requirements motivates us to provide unique stimulation strategies for each project.

• Antigen-Specific CD8+ T Cell based Artificial T Cell Stimulator Development Service
• Antigen-Specific CD4+ T Cell based Artificial T Cell Stimulator Development Service
• Polyclonal CD3+ T Cell based Artificial T Cell Stimulator Development Service
• Chimeric Antigen Receptor Transduced T Cell based Artificial T Cell Stimulator Development Service
• Natural Killer Cell based Artificial T Cell Stimulator Development Service

To explore the development of a customized, flexible artificial T cell stimulator specifically for iNKT cell stimulation, please follow the link to contact us and discuss your unique project requirements.

Reference

1. Wolf, Benjamin J., Jiyoung Elizabeth Choi, and Mark A. Exley. "Novel approaches to exploiting invariant NKT cells in cancer immunotherapy." Frontiers in Immunology 9 (2018): 384. Distributed under Open Access License CC BY 4.0, without modification.